Detection of androgen receptor (AR) variant 7 (AR-V7) is emerging as a clinically important
biomarker in castrate resistant prostate cancer (CRPC). Detection is possible from tumor …

Despite the recent approval and widespread use of abiraterone acetate and enzalutamide
for the treatment of castration-resistant prostate cancer (CRPC), this disease still poses …

Prostate cancer progression is controlled by the androgen receptor and new blood vessel
formation, or angiogenesis, which promotes metastatic prostate cancer growth …

Over the last few years, immunotherapy, in particular, immune checkpoint inhibitor therapy,
has revolutionized the treatment of several types of cancer. At the same time, the uptake in …

Introduction: Prostate cancer is a highly heterogeneous disease, with remarkably different
prognosis across all stages. Increased circulating tumor cell (CTC) count (≥ 5) using the …

Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by
androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most …

Rationale: Aberrant androgen receptor (AR) signaling via full-length AR (AR-FL) and
constitutively active AR variant 7 (AR-V7) plays a key role in the development of castration …

Androgen signaling is a critical determinant of timely and proper development of all male
organs including the prostate. Maturation of prostate and its neoplastic transformation is …

The therapeutic landscape of metastatic hormone sensitive and metastatic castration-
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …

Prostate cancer (PCa) is the second most common cause of cancer‐related mortality in men
in the United States. The androgen receptor (AR) and the physiological pathways it …